Zebinix eslicarbazepine acetate: Additional Phase III data

Data from a 1-year extension of the Phase III BIA-2093-301 trial in 95 patients showed that eslicarbazepine as add-on therapy resulted in reduced mean seizure frequency by 61.8%. Also, 64.9% of patien...